Shai Ashkenazi Appointed to BiondVax's Scientific Advisory Board

Shai Ashkenazi Appointed to BiondVax's Scientific Advisory Board

An experienced clinician-researcher, Prof

Ashkenazi has guided multiple vaccines through

clinical and regulatory approval phases to market.

Ness Ziona, Israel - September 7, 2016 - BiondVax

Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing

a vaccine against current and future seasonal and pandemic influenza strains, is pleased to announce the appointment of Professor

Shai Ashkenazi to its Scientific Advisory Board (SAB).

Ashkenazi is a clinical and regulatory vaccine expert, with significant

contributions to flu and other infectious disease vaccine research and development. He has served on the clinical trial advisory

boards for the development of a pediatric flu vaccine, vaccines for enteric infections, as well as other infectious diseases.

Ashkenazi has a deep understanding and experience with BiondVax's

universal flu vaccine as he served as the head of the data and safety monitoring board (DSMB) in all of the company's clinical

trials in Israel and abroad.

Professor Ashkenazi commented, "I am excited to join

BiondVax's SAB and to be part of the efforts to bring better protection against the flu in order to save lives."

The head of BiondVax's Scientific Advisory Board, Professor

Ruth Arnon stated, "We're honored Prof. Ashkenazi has joined the team. His breadth of experience in marshalling

pharma products through clinical trials, regulatory and marketing approval will be of great value as BiondVax begins to progress

towards Phase 3 trials. Our team - the SAB, board, and employees - are well positioned to achieve approval for M-001 as the

first universal flu vaccine."

Among other positions, Ashkenazi currently holds the Lea and Arieh

Pickel Chair for Pediatric Research at the Sackler Faculty of Medicine, Tel Aviv University. He is also Chair of the Department

of Pediatrics A at Schneider Children's Medical Center and Head of the Research Laboratory for Pediatric Infectious Diseases

at the Felsenstein Medical Research Center.

Ashkenazi is an editorial board member of several international

medical journals, has served on numerous national and international committees, authored over 200 medical publications and is editor

of the Israeli Textbook of Pediatrics.

About BiondVax Pharmaceuticals Ltd

BiondVax is a clinical phase biopharmaceutical

company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and

pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and

common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting

effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. Please visit www.biondvax.com.

For further information, please contact:

Forward Looking Statements

This press release contains forward-looking

statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe,"

"intend," "plan," "continue," "may," "will," "anticipate," and similar

expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties

reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties

and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals

Ltd. Risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process

with uncertain outcome, the results of the current Phase 2 & contemplated phase 3 trials, the adequacy of available cash resources

to fund product development and commercialization and the ability to raise capital when needed. The risks, uncertainties and assumptions

referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our annual

report for the year ended December 31, 2015 on Form 20-F filed with the Securities and Exchange Commission on April 27, 2016. BiondVax

Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements.